BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

Neurology INDICATION: Depression Mouse studies suggest promoting KCNQ3 expression or opening potassium channels could help treat major depressive disorder (MDD). In a mouse model of chronic depression, expression of KCNQ3 in ventral tegmental area dopaminergic...
BC Week In Review | Feb 15, 2016
Company News

Meda, Mylan deal

Generics company Mylan will acquire specialty pharma Meda for SEK165 per share in cash and stock. The deal values Meda at about SEK83.6 billion ($9.9 billion), or SEK60.3 billion ($7.1 billion) net of debt. The...
BC Extra | Feb 11, 2016
Company News

Mylan acquiring Meda

Generics company Mylan N.V. (NASDAQ:MYL) will acquire Meda AB (SSE:MEDAA) for about SEK83.6 billion ($9.9 billion) in cash and stock, or SEK60.3 billion ($7.1 billion) net of debt. Meda makes specialty pharma products, OTC drugs...
BC Week In Review | Sep 14, 2015
Company News

Breckenridge sales and marketing update

Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the U.S. The antihistamine is approved to treat seasonal allergic rhinitis in patients at least five years old and...
BC Week In Review | May 18, 2015
Company News

GlaxoSmithKline, The ALS Association, Harvard, Massachusetts General Hospital deal

The ALS Association, the university’s Harvard Stem Cell Institute, the hospital’s Neurological Clinical Research Institute and GlaxoSmithKline partnered to conduct a clinical trial to evaluate antiepileptic drug Potiga ezogabine in patients with amyotrophic lateral sclerosis....
BC Week In Review | Mar 2, 2015
Clinical News

Dymista azelastine/fluticasone regulatory update

FDA approved an sNDA from Meda for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients ages 6-11 who require treatment with both components. In 2012, FDA approved the product -- a combination of azelastine...
BC Innovations | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Potassium channel

Neurology INDICATION: Stroke Mouse studies suggest M-type potassium channel openers could improve recovery following stroke. In mouse photothrombotic and middle cerebral artery occlusion models of stroke, treatment with different M-type channel openers including Trobalt retigabine...
BC Week In Review | Feb 9, 2015
Company News

BioDelivery, Meda deal

Meda returned North American rights to Onsolis fentanyl buccal soluble film to BioDelivery. Meda received rights to Onsolis in 2007. BioDelivery plans to re-partner the drug in the U.S. and will work with the FDA...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Nov 24, 2014
Company News

Rottapharm Madaus, Meda deal

Meda completed its acquisition of Rottapharm for SEK15.3 billion ($2.1 billion) in cash and 30 million shares valued SEK2.9 billion ($406.4 million) based on Meda’s close of SEK96.70 on Oct. 9, the day before the...
Items per page:
1 - 10 of 318
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

Neurology INDICATION: Depression Mouse studies suggest promoting KCNQ3 expression or opening potassium channels could help treat major depressive disorder (MDD). In a mouse model of chronic depression, expression of KCNQ3 in ventral tegmental area dopaminergic...
BC Week In Review | Feb 15, 2016
Company News

Meda, Mylan deal

Generics company Mylan will acquire specialty pharma Meda for SEK165 per share in cash and stock. The deal values Meda at about SEK83.6 billion ($9.9 billion), or SEK60.3 billion ($7.1 billion) net of debt. The...
BC Extra | Feb 11, 2016
Company News

Mylan acquiring Meda

Generics company Mylan N.V. (NASDAQ:MYL) will acquire Meda AB (SSE:MEDAA) for about SEK83.6 billion ($9.9 billion) in cash and stock, or SEK60.3 billion ($7.1 billion) net of debt. Meda makes specialty pharma products, OTC drugs...
BC Week In Review | Sep 14, 2015
Company News

Breckenridge sales and marketing update

Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the U.S. The antihistamine is approved to treat seasonal allergic rhinitis in patients at least five years old and...
BC Week In Review | May 18, 2015
Company News

GlaxoSmithKline, The ALS Association, Harvard, Massachusetts General Hospital deal

The ALS Association, the university’s Harvard Stem Cell Institute, the hospital’s Neurological Clinical Research Institute and GlaxoSmithKline partnered to conduct a clinical trial to evaluate antiepileptic drug Potiga ezogabine in patients with amyotrophic lateral sclerosis....
BC Week In Review | Mar 2, 2015
Clinical News

Dymista azelastine/fluticasone regulatory update

FDA approved an sNDA from Meda for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients ages 6-11 who require treatment with both components. In 2012, FDA approved the product -- a combination of azelastine...
BC Innovations | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Potassium channel

Neurology INDICATION: Stroke Mouse studies suggest M-type potassium channel openers could improve recovery following stroke. In mouse photothrombotic and middle cerebral artery occlusion models of stroke, treatment with different M-type channel openers including Trobalt retigabine...
BC Week In Review | Feb 9, 2015
Company News

BioDelivery, Meda deal

Meda returned North American rights to Onsolis fentanyl buccal soluble film to BioDelivery. Meda received rights to Onsolis in 2007. BioDelivery plans to re-partner the drug in the U.S. and will work with the FDA...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Nov 24, 2014
Company News

Rottapharm Madaus, Meda deal

Meda completed its acquisition of Rottapharm for SEK15.3 billion ($2.1 billion) in cash and 30 million shares valued SEK2.9 billion ($406.4 million) based on Meda’s close of SEK96.70 on Oct. 9, the day before the...
Items per page:
1 - 10 of 318